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Abstract
Background: The impact of body composition on outcomes after surgery for colorectal liver metastases
(CRLM) remains unclear. The aim of the present study was to determine the influence of sarcopenia,
obesity and sarcopenic obesity on morbidity, disease-free (DFS) and overall survival (OS).
Method: Between 2005 and 2012, all patients undergoing a partial liver resection for CRLM in the
Maastricht University Medical Centre, and who underwent computed tomography (CT) imaging within 3
months before liver surgery, were included. Body composition was primarily based on pre-operative CT
measurements. Sarcopenia was based on total muscle area at the level of the third lumbar vertebra and
predefined body mass index (BMI)- and gender-specific cut-off values for sarcopenia were used. Body fat
percentages were calculated and the top 40% for men and women were considered obese.
Results: Of the 171 included patients undergoing liver surgery for CRLM, 80 (46.8%) patients were
sarcopenic, 69 (40.4%) obese and 49 (28.7%) sarcopenic obese. The presence of sarcopenia, obesity or
sarcopenic obesity did not affect the complication rates. However, readmission rates were significantly
increased in patients with (sarcopenic) obesity (P < 0.05). Surprisingly, obesity seemed to prolong OS (P
= 0.021) and was identified as an independent predictor [hazard ratio (HR):0.58 and P = 0.046] for better
OS. Sarcopenia and sarcopenic obesity did not affect DFS or OS.
Conclusion: Sarcopenia, obesity and sarcopenic obesity did not worsen DFS, OS and complication
rates after a partial liver resection for CRLM.
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Introduction
A liver resection for colorectal liver metastases (CRLM) is increas-
ingly being performed. The criteria for resectability have been
expanded as a result of improved surgical possibilities, more effec-
tive chemotherapy and improved peri-operative care.1–3 As a
result, more extensive parenchymal resections are now performed.
As a consequence the risk of post-resectional liver failure and
other major complications has increased. Therefore the role of
pre-operative assessment has gained more importance. Liver
volumetry and functional liver assessment are widely accepted in
the workup of patients undergoing a major liver resection.4–6 In
this context body composition is increasingly being brought to the
attention, as it was reported to be associated with impaired
outcome.7–10 Currently, there are not many studies that investi-
gated the impact of body composition on outcome and survival
after surgery for CRLM.
Cancer-related weight loss (cachexia) occurs in up to 30% of
patients with colorectal liver metastases.11 The effect of reduced
muscle mass (sarcopenia) on outcome and survival after liver
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surgery has been analysed in relatively small studies, but so far
there is no consensus about its influence on outcome.8–10,12 Some
previous studies have identified sarcopenia as an independent
predictor negatively influencing overall survival (OS) and disease-
free survival (DFS),8,10 but others did not.9 Some authors con-
cluded that sarcopenia is associated with higher morbidity rates
after liver surgery.9 Recently it has been demonstrated that total
liver volume in sarcopenic patients was disproportionally smaller
compared with patients without sarcopenia,13 and this could con-
tribute to increased morbidity after liver surgery.
At the other extreme of physiognomy, the effect of obesity on
outcome in patients with malignant disease also remains contro-
versial.14 Obesity seems to be associated with a higher risk of
post-operative morbidity and mortality after liver surgery.7 There
is, however, no consensus on the impact of obesity on DFS and
OS. Depending on the underlying malignant disease, conflicting
results have been reported on OS in patients with obesity versus
patients with a normal weight,10,15 with some even reporting there
was a protective effect of obesity.16,17
The combination of sarcopenia and obesity (sarcopenic
obesity) is an independent predictor of worse OS in patients
undergoing pulmonary, gastrointestinal and pancreatic cancer
surgery.18–20 However, to the authors’ knowledge the effect of
sarcopenic obesity on complications and long-term outcomes
after liver surgery has not been described.
The aim of the present study was to explore whether
sarcopenia, obesity and sarcopenic obesity predispose for morbid-
ity, early recurrence and reduced OS in patients undergoing a
partial liver resection for CRLM.
Material and methods
Patients
A prospective database was used to identify patients that under-
went a partial hepatectomy at the Maastricht University –Medical
Centre Hepato-Pancreato-Biliary (HPB) unit between 2005 and
2012. Only patients with CRLM, staged by a four-phase contrast
enhanced abdominal computed tomography (CT) scan up to 3
months before resection, were included. Patients with CT scans of
poor quality were excluded as body composition measurements
could not be performed in these patients. Moreover, patients who
eventually did not undergo a liver resection were excluded.
Patients without information on weight, height and body mass
index (BMI) were also excluded. All patients were discussed at a
pre-operative multidisciplinary liver board. Patient-specific
co-morbidities and diagnostic procedures were assessed and the
definitive treatment strategy was decided in consensus. Induction
chemotherapy in patients with irresectable tumours, liver resec-
tion combined with tumour ablation, pre-operative portal vein
embolization (PVE), liver first policy in rectal cancer and a repeat
hepatectomy were all among potential treatment options. Vascular
reconstructions were occasionally used. All patients were treated
within an Enhanced Recovery After Surgery (ERAS®) peri-
operative care programme.21
Liver resections
All liver resections were classified in accordance with the IHPBA
Brisbane nomenclature.22 Liver resection was performed as
described previously.23 After mobilization of the liver, intra-
operative ultrasound gave insight in the feasibility of the pre-
operatively planned surgical procedure. A transection was
performed using a Cavitron Ultrasonic Surgical Aspirator (CUSA
system 200 Macrodissector; Cavitron Surgical Systems, Stamford,
CT, USA). To prevent excessive blood loss the central venous
pressure was maintained below 5 cm H2O during transection.
Hilar inflow occlusion (Pringle manoeuvre) was performed for a
maximum of 30 min in case of increased bleeding risk. Haemo-
stasis was achieved using bipolar coagulation (Force GSU System;
Valleylab, Boulder, CO, USA), sutures and clips.
Methods
Body composition
The presence of sarcopenia was assessed through measurements
of skeletal muscle areas by one researcher (T.J.A.v.N.) with the use
of the OsiriX® programme on contrast-enhanced pre-operative
CT scans on a 2.8-GHz Intel Core 2 Duo 24” iMac (Apple Inc.,
Cupertino, CA, USA). A threshold range between −30 and 110
Hounsfield Units was set to semi-automatically outline muscle
areas at the transversal level of the third lumbar vertebra (L3) as
recently described. The mean of measurements on two adjacent
CT slices at the L3 level was used to calculate the L3 skeletal muscle
index (L3 MI) by correcting it for height. Sarcopenia was defined
as an L3 MI <41 cm2/m2 in women, <43 cm2/m2 in men with a
BMI <25, and <53 cm2/m2 in men with a BMI >25 as these cut-off
values showed an association with mortality.20 The body surface
area was estimated using the Mosteller formula, {[height (cm) *
weight (kg)]/3600}1/2.24 Total fat-free body mass (kg) was esti-
mated as: 0.30 * (skeletal muscle surface area at L3 in cm2) + 6.06.18
Body fat percentage was calculated as: [body weight (kg) – fat free
body mass (kg)]/body weight (kg). Obesity was based on body fat
percentages. Cut-off values for obesity were >44.4% for women
and >35.7% for men, based on the top two body fat percentage
quintiles in our study as is conventional for studies evaluating
sarcopenic obesity.25–27 Sarcopenic obesity was defined as the pres-
ence of both sarcopenia and obesity according to these definitions.
Outcome parameters
The primary endpoint of the study was OS. Secondary endpoints
were complications, post-operative mortality, hospital length of
stay (LOS) and DFS. Complications were registered daily using
National Surgical Adverse Event Registration (LHCR) software28
of the Dutch Association of General Surgery before 2009 and the
hospital information system (SAP, Walldorf, Germany) after-
wards. The post-operative course of all discharged patients was
discussed at the surgical morbidity meeting. Post-operative
90-day morbidity was graded according to the Dindo–Clavien
classification.29 Complications requiring readmission were also
included in the complication registration. Complications with a
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Dindo–Clavien score ≤2 were considered minor complications
whereas complications with a score ≥3a were considered major
complications. Moreover, the liver surgery-specific composite
endpoint (LSSCEP), composed of ascites, post-resectional liver
failure, bile leakage, intra-abdominal haemorrhage, intra-
abdominal abscess and mortality, was used to assess liver surgery-
specific morbidity.30 Patient demographics were registered and
information on co-morbidity, location and TNM stage of the
primary tumour and time point of occurrence of liver metastases
were retrieved from patient charts. The size of the metastases and
the resection margins were retrieved from pathology reports. R0
resections were defined as resections with a tumour-free resection
surface.
Follow-up consisted of outpatient visits with plasma
carcinoembryonic antigen levels every 3 months and liver imaging
twice in the first 2 years and annually up to 5 years after surgery.
In case of recurrence, patients were assessed with positron emis-
sion tomography (PET)-CT and the indication for repeat liver or
lung surgery was again discussed at a multidisciplinary liver
meeting. OS and DFS after liver resection were calculated in per-
centages and registered in months using the time period between
the date of surgery and death or recurrence, respectively. In the
case of two-stage hepatectomies, DFS was calculated as the time
period between the first stage operation and the recurrence of
metastases after the second stage operation.
Statistical analysis
Data were analysed using SPSS version 21.0 (SPSS Inc., Chicago,
IL). Data are expressed as the median and range or percentages or
survival in months (95% confidential interval). The chi-square
test was used to analyse categorical data whereas continuous data
were analysed using the Mann–Whitney U-test. Time to recur-
rence and OS were calculated with the Kaplan–Meier (censored)
method using the date of liver surgery as a reference date. A level
of P < 0.05 was considered to be statistically significant. Relevant
clinicopathological variables associated with OS and DFS were
examined using univariable and, where applicable, multivariable
Cox proportional hazards regression. For the multivariable
models, a univariable inclusion criterion of P ≤ 0.15 was used.
Results
Four out of 175 patients (2.3%) were excluded for various reasons
(1 patient because no resection was performed, 1 patient due to a
poor quality CT scan and 2 patients due to a lack of information
on weight, height or BMI.). A total of 171 patients with a median
follow-up of 21 [1–90] months, were included. Demographics are
shown in Table 1. Complications are shown in Table 2. The
median hospital LOS was 8 [2–92] days. The median DFS was 16
[confidence interval (CI) 9–22] months with a 1 and 3 year DFS
rate of 57.1% and 36.0%, respectively. The median OS was 54
months (CI 45–62) and 1, 3 and 5 year OS rates were 91.8%,
65.6% and 43.1%, respectively.
Sarcopenia
According to the predefined cut-off values for sarcopenia, 80
(46.8%) patients were considered sarcopenic (Table 1). Patients
with sarcopenia had a significantly increased percentage body fat
(42.2 [26.1–57.3] versus 32.2 [6.8–62.2]%,P < 0.001). Major com-
plications were equally common in sarcopenic and non-
sarcopenic patients (26.3 versus 18.7%, P = 0.235). Moreover,
the presence of the LSSCEP (P = 0.230), initial hospital LOS
(P = 0.202) and readmission rates (P = 0.283) did not differ
Table 1 Patient characteristics
Variables, median [range] All patients n = 171
Patient characteristics
Median age [range], y 64 [24–86]
ASA >2 28 (16.4)
Patients with PVE (%) 4 (2.3)
Weight [range], kg 75 [47–119]
Height [range], (cm) 172 [149–195]
BMI [range], (kg/m2) 25.7 [18.4–42.8]
Body composition
L3 MI [range] (cm2/m2) 46.4 [31.7–71.1]
Sarcopenia (%) 80 (46.8)
Fat free body mass [range] (kg) 48.1 [29.9–79.9]
Fat mass [range] (kg) 28.4 [3.7–73.4]
Body fat % [range] 36.9 [6.8–62.2]
Obesity (%) 69 (40.4)
Sarcopenic obesity (%) 49 (28.7)
Body surface area [range] (m2) 1.89 [1.42–2.53]
Laboratory testing [range] (normal)
Bilirubin (mg/dl) (<20.0) 11.6 [2.7–47.0]
INR ratio (0.80-1.20) 0.99 [0.91–2.91]
Platelets (10E9/l) (130–350) 226 [3–635]
Prothrombin time (s) (9.9–11.5) 10.6 [9.7–31.7]
Tumour
Size of largest tumour [range] (mm) 25 [2–130]
Patients with tumour >5 cm (%) 21 (12.5)
Bilateral (%) 77 (45.0)
Number of tumours [range] 2 [1–13]
Patients with tumours >3 (%) 32 (18.7)
Concomittant extrahepatic disease 14 (8.2)
Resection type (%)
Left hemihepatectomy (%) 4 (2.3)
Right hemihepatectomy (%) 45 (26.3)
Extended right hepatectomy (%) 4 (2.3)
Central (%) 6 (3.5)
(Multiple) segmentectomy (%) 110 (64.3)
ASA, American Society of Anesthesiologists; PVE, portal vein
embolization; BMI, body mass index; MI, muscle index; INR, International
Normalized Ratio.
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significantly between the groups (Table 3). The median DFS and
OS were not significantly different between patients with and
patients without sarcopenia (Fig. 1).
Obesity
Based on our definition 69 (40.4%) patients met the criteria for
obesity. General patient characteristics, not related with obesity,
were comparable between the two groups. Obese men had signifi-
cantly lower L3 muscle indices compared with men without
obesity (46.5 [34.9–63.2] versus 52.5 [40.2–71.1] cm2/m2, P <
0.001) indicating a higher incidence of sarcopenia. There was no
difference in morbidity between the two groups. However, the
readmission rate was significantly higher in obese patients (21.7
versus 7.8%, P = 0.009) (Table 3). Moreover, readmissions tended
to be more often as a result of infection in the obese (53.3 versus
12.5%, P = 0.056). DFS did not differ significantly between obese
and non-obese patients. OS was significantly longer in obese
patients compared with non-obese patients [79 (CI 45–113)
versus 46 (CI 37–57) months, P = 0.021] (Fig. 2). Non-obese
women showed decreased OS compared with obese women [40
(CI 22–58) versus 79 (CI 48–109) months, P = 0.012], whereas
non-obese men did not (P = 0.325).
Sarcopenic-obesity
Sarcopenic obesity was present in 49 patients (28.7%). Major
complications (P = 0.206), the occurrence of one or more of the
items of the liver surgery-specific composite endpoint (P = 0.225)
and the initial hospital LOS (P = 0.579) were all comparable
between sarcopenic-obese patients and patients without
sarcopenic obesity. Readmissions were more frequent in patients
with sarcopenic obesity (22.4 versus 9.8%, P = 0.029) (Table 3)
and were caused by infections in 45.5% of the sarcopenic obese
and 33.3% of patients without sarcopenic obesity (P = 0.552). The
median DFS (22 [0–45] versus 15 [11–18] months, P = 0.337) and
OS (71 [38–58] versus 48 [38–58] months, P = 0.135) were not
significantly different between sarcopenic-obese patients and
patients without sarcopenic obesity, respectively.
Predictors of DFS and OS
Univariable analyses showed that having >3 metastases, concomi-
tant extrahepatic disease and pre-operative chemotherapy were
significant prognostic factors of DFS (P < 0.05). Four more factors
(P < 0.15) were added to the multivariable analysis. As the before-
mentioned results indicated that obesity might be a protective
factor for OS, obesity was also added to the multivariable analysis.
After multivariable analysis obesity (HR: 0.73 and P = 0.161)
could not be identified as an independent factor for better DFS.
The only significant independent negative prognostic factors
affecting DSF was having concomitant extrahepatic disease (HR:
2.48 and P = 0.006) (Table 4).
Significant prognostic factors for OS after univariable analyses
were female gender, obesity, concomitant extrahepatic disease,
major complications and the liver surgery specific composite end-
point (P < 0.05). One more factor (positive primary colorectal
cancer lymph nodes) was added to the multivariable analysis
because of borderline significance (P < 0.15). After multivariable
analysis, obesity (HR: 0.58 and P = 0.046) was identified as an
independent protective factor for OS. Concomitant extrahepatic
disease (HR: 2.32 and P = 0.020) was the only significant negative
prognostic factors affecting OS. Moreover, the LSSCEP (HR: 1.65
and P = 0.076), positive primary colorectal lymph nodes (HR: 1.60
and P = 0.078) and female gender (HR: 1.54 and P = 0.071) all
showed tendencies to be negative prognostic factors for OS
(Table 5).
Discussion
To date, the influence of body composition on outcomes after liver
surgery for colorectal liver metastases has not been described
Table 2 Complications
Variables All patients
N = 171
Grading of complications
Number of patients with complications (%) 78 (45.6)
Minor complications present 40 (23.4)
Dindo–Clavien grade 1 9 (5.3)
Dindo–Clavien grade 2 31 (18.1)
Major complications present 38 (22.2)
Dindo–Clavien grade 3a 27 (15.8)
Dindo–Clavien grade 3b 4 (2.3)
Dindo–Clavien grade 4a 5 (2.9)
Dindo–Clavien grade 4b 1 (0.6)
Dindo–Clavien grade 5 1 (0.6)
Liver surgery-specific composite endpoint (LSSCEP)
Number of patients with 1 or more items of LSSCEP 28 (16.4)
Ascites 5 (2.9)
Post-resectional liver failure 4 (2.3)
Bile leak 8 (4.7)
Intra-abdominal haemorrhage 1 (0.6)
Intra-abdominal abscess 21 (12.3)
Mortality 1 (0.6)
Other complications
Cardiovascular 9 (5.3)
Pulmonary 14 (8.2)
Renal 5 (2.9)
Gastro-intestinal 34 (19.1)
Neurological 4 (2.4)
Haematological 4 (2.4)
Sepsis 6 (3.5)
Wound infection 12 (7.0)
Readmissions
Number of patients readmitted 23 (13.5)
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clearly. This study showed that sarcopenia, obesity and sarcopenic
obesity did not seem to influence (major) complication rates after
a liver resection for CRLM. Readmission rates, however, were
significantly increased in patients with obesity or sarcopenic
obesity. Sarcopenia, obesity and sarcopenic obesity did not seem
to influence OS adversely. In obese patients, the median OS was
nearly twice as long compared with patients without obesity.
Moreover, after multivariable analysis, obesity was identified as an
independent factor for better OS.
Peng et al. previously looked at the effect of sarcopenia on
outcome in patients operated for CRLM and, in line with the
present results, they concluded that sarcopenia did not result in
worse DFS and OS.9 In contrast, others showed that sarcopenic
patients undergoing a liver resection for hepatocellular carcinoma
or CRLM had a worse prognosis concerning DFS and OS.8,10 Some
studies showed increased morbidity after a liver resection in
sarcopenic patients in contrast to the present study where mor-
bidity and mortality were comparable in patients with and
without sarcopenia.9
Differences in outcome between studies might well be
explained by the different L3 muscle index cut-off values used to
define sarcopenia. Martin et al. published sex-specific BMI
dependent cut-off values for the L3 muscle index that were asso-
ciated with mortality, based on >1400 patients with pulmonary
and gastrointestinal cancer.18 Using these cut-off values, the
present study reported an incidence of sarcopenia of 47%. Some
studies used cut-off values calculated by Prado et al. that are based
on obese patients only.18 Others used cut-off values for the L3
muscle index calculated by van Vledder et al. based on a relatively
small series of patients with colorectal liver metastases without
taking BMI into account. These cut-off values lead to an incidence
of sarcopenia between 19% and 40%.8,10 A large epidemiological
study by Baumgartner et al., using dual-energy X-ray (DXA),
revealed an incidence of sarcopenia of about 20% in patients <70
years of age rising to over 50% in patients aged >80 years in a
healthy population.31 It should be realized that cachexia (cancer-
related loss of adipose tissue and skeletal muscle mass) also con-
tributes to muscle wasting in up to 30% of patients with CRLM.11
Therefore this may increase the prevalence of sarcopenia substan-
tially in studies including patients with colorectal liver metasta-
ses.32 We believe that muscle wasting is underreported in studies
showing increased morbidity and worse long-term outcomes in
sarcopenics, and these studies may have selected predominantly
severe cases of muscle wasting.8,10
The present study showed a clear increase of the OS in obese
patients compared with their non-obese counterparts. Moreover,
obesity was an independent predictor positively affecting OS.
These findings, also called the obesity paradox,33 are in line with
recently published studies in patients with other malignancies and
the elderly, also showing the survival benefit for the obese.16,17,33,34
To our knowledge this seemingly protective effect of increased
percentage body fat has not yet been described for CRLM. Vigano
et al. reported higher minor morbidity in the obese, but also
concluded that major morbidity was comparable.35 Others
found that obesity influenced major morbidity.36 Possibly the
increased percentage body fat in this population was not as
Table 3 Features associated with sarcopenia, obesity and sarcopenic obesity
Sarcopenia Obesity Sarcopenic-obesity
No
(n = 91)
Yes
(n = 80)
P No
(n = 102)
Yes
(n = 69)
P No
(n = 122)
Yes
(n = 49)
P
Patient characteristics
Median age [range] (years) 64 [24–83] 65 [39–86] 0.628 64 [24–83] 66 [41–86] 0.184 64 [24–83] 67 [41–86] 0.262
Sex, number of males (%) 59 (64.8) 45 (56.3) 0.251 62 (60.8) 42 (60.9) 0.991 71 (58.2) 33 (67.3) 0.268
Patients with ASA >2 (%) 15 (16.5) 13 (16.3) 0.967 18 (17.6) 10 (14.5) 0.582 21 (17.2) 7 (14.3) 0.640
Co-morbidities present (%) 47 (51.6) 36 (45.0) 0.385 52 (51.0) 31 (44.9) 0.437 60 (49.2) 23 (46.9) 0.791
Patients with PVE (%) 2 (2.2) 2 (2.5) 0.896 2 (2.0) 2 (2.9) 0.691 3 (2.5) 1 (2.0) 0.870
Surgery
Major liver resections (≥3 liver segments) (%) 28 (30.8) 33 (41.3) 0.153 34 (33.3) 27 (39.1) 0.438 45 (36.9) 16 (32.7) 0.601
R0 resections (%) 65 (71.4) 58 (72.5) 0.876 75 (73.5) 48 (69.6) 0.571 86 (70.5) 37 (75.5) 0.509
Admission
Initial hospital length of stay [range] (days) 8 [2–90] 8 [4–92] 0.202 8 [2–92] 8 [5–90] 0.746 8 [2–92] 8 [5–84] 0.579
Complications present (%) 45 (49.5) 33 (41.3) 0.283 46 (45.1) 32 (46.4) 0.869 55 (45.1) 23 (46.9) 0.826
Minor complications (%) 28 (30.8) 12 (15.0) 0.015 26 (25.5) 14 (20.3) 0.431 31 (25.4) 9 (18.4) 0.325
Major complications (%) 17 (18.7) 21 (26.3) 0.235 20 (19.6) 18 (26.1) 0.317 24 (19.7) 14 (28.6) 0.206
Liver specific composite endpoint present (%) 12 (13.2) 16 (20.0) 0.230 16 (15.7) 12 (17.4) 0.768 18 (14.8) 10 (20.4) 0.366
Readmissions
Patients readmitted (%) 10 (11.0) 13 (16.3) 0.314 8 (7.8) 15 (21.7) 0.009 12 (9.8) 11 (22.4) 0.029
ASA, American Society of Anesthesiologists; PVE, portal vein embolization.
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Figure 1 Kaplan–Meier curves of disease-free (DFS) (top) and overall
survival (OS) (bottom) for patients with and without sarcopenia. The
median DFS was 20 [6–34] and 14 [9–18] months with 1/3 years DFS
rates of 62.7/40.9% and 52.3/31.7% in patients with and without
sarcopenia. The median OS was 54 [36–71] and 49 [34–64] months
with 1/3/5 years OS rates of 92.5/69.0/45.8% and 91.2/62.6/40.8%
in patients with and without sarcopenia
Figure 2 Kaplan–Meier curves of disease-free (DFS) (top) and overall
survival (OS) (bottom) for patients with and without obesity. The
median DFS was 22 [2–42] and 13 [9–17] months with 1/3 years DFS
rates of 65.1/45.5% and 51.5/29.5% in patients with and without
obesity. The median OS was 79 [45–113] and 46 [37–57] months
with 1/3/5 years OS rates of 92.8/75.7/60.9% and 91.1/59.5/32.4%
in patients with and without obesity
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profound as needed to increase morbidity significantly,33 but just
sufficient to increase the physiological reserve and have a positive
effect on OS.
In order to prevent possible confounders, this study was per-
formed among a homogenous population of only patients with
CRLM. Moreover, we based sarcopenia on CT-based measure-
ments, the gold standard for estimating muscle mass.37 The main
drawbacks, however, of the present study are the retrospective
design and the calculation of percentage body fat. Although cal-
culation of percentage body fat based on the skeletal muscle area
at the level of the third lumbar vertebra is believed reasonably
accurate,18 measuring the body fat area on CT might be more
reliable. Moreover, a bigger sample size might have enabled us to
identify some factors as statistically significant that were now
borderline significant.
In conclusion, the present study provides new insights in liver
surgery for CRLM in relation to body composition. Sarcopenia,
obesity and sarcopenic obesity do not seem to increase morbid-
ity. However, obese and sarcopenic-obese patients were signifi-
cantly more often readmitted. Increased body fat seemed to
prolong OS and obesity was identified as an independent pre-
dictor of better OS. New studies on the effect of body compo-
sition disturbances on outcome after surgery should take the
severity of obesity and sarcopenia into account as it might be
that especially mild-to-moderate obesity has a protective effect
on OS and severe obesity or severe sarcopenia have negative
effects on complications, DFS and OS.
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Table 4 Predictors for disease free survival, uni- and multivariable analysis
Prognostic factor Univariable Multivariable
P value HR (95% CI) P value HR (95% CI)
Age (years) 0.483 0.993 (0.975–1.012)
Female gender 0.166 1.317 (0.892–1.945)
ASA 3 (versus ASA 1/2) 0.130 0.628 (0.344–1.147) 0.359 0.738 (0.386–1.412)
Co-morbidities present 0.176 0.764 (0.518–1.128)
Primary site
Colon Reference
Rectum 0.635 1.110 (0.721–1.710)
Primary CRC T stage
T1-2 Reference
T3-4 0.735 1.106 (0.616–1.987)
Positive primary CRC lymph nodes 0.120 1.408 (0.915–2.166) 0.189 1.347 (0.863–2.102)
Sarcopenia* 0.483 0.871 (0.591–1.283)
Obesity 0.211 0.775 (0.520–1.156) 0.161 0.727 (0.466–135)
Sarcopenic obesity* 0.338 0.807 (0.519–1.252)
>3 CRLM 0.017 1.736 (1.104–2.732) 0.175 1.414 (0.857–2.333)
Diameter of largest lesion ≥5 cm 0.360 0.754 (0.411–1.381)
Concomitant extrahepatic disease 0.001 2.697 (1.464–4.971) 0.006 2.483 (1.296–4.756)
Bilateral 0.202 1.288 (0.873–1.899)
Major liver resection (versus minor) 0.404 0.842 (0.562–1.261)
Duration of surgery (hours) 0.986 1.001 (0.880–1.139)
Blood loss during surgery (1000 ml) 0.982 1.000 (1.000–1.000)
Positive surgical margin (R1 versus R0) 0.090 1.433 (0.945–2.172) 0.118 1.437 (0.913–2.263)
Liver surgery-specific CEP 0.063 1.581 (0.975–2.563) 0.216 1.374 (0.830–2.276)
Complications*
None Reference
Minor (Dindo–Clavien grade 1–2) 0.724 1.092 (0.669–1.782)
Major (Dindo–Clavien grade ≥3a) 0.062 1.558 (0.978–2.481)
Pre-operative chemotherapy 0.033 1.651 (1.042–2.618) 0.385 1.249 (0.756–2.062)
Adjuvant chemotherapy 0.332 0.825 (0.560–1.217)
*/**Excluded from multivariable analysis owing to collinearity with obesity (*) or the liver surgery-specific composite endpoint (**).
ASA, American Society of Anesthesiologists; CEP, composite endpoint; CRC, colorectal cancer.
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